• Nausea

Aponvie Generic Name & Formulations

General Description

Aprepitant 32mg/4.4mL (7.2mg/mL); emulsion for IV inj; contains egg lecithin, ethanol, soybean oil, sucrose.

Pharmacological Class

Substance P/NK1 receptor antagonist.

How Supplied

Single-dose vials—10


Generic Availability


Mechanism of Action

Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for postoperative nausea and vomiting (PONV). Aprepitant has been shown in animal models to inhibit emesis via central actions.

Aponvie Indications


Prevention of postoperative nausea and vomiting (PONV).

Limitations of Use

Not for treating established nausea and vomiting.

Aponvie Dosage and Administration


Give prior to induction of anesthesia.  32mg IV over 30secs. Flush with normal saline prior to and after administration. 


Not established.

Aponvie Contraindications


Concomitant pimozide. 

Aponvie Boxed Warnings

Not Applicable

Aponvie Warnings/Precautions


Monitor for hypersensitivity reactions; discontinue and treat appropriately if occur; do not reinitiate if symptoms developed with previous use. Severe hepatic impairment. Pregnancy: avoid. Advise females of reproductive potential using hormonal contraceptives to use an effective alternative or back-up non-hormonal contraception for 1 month after administration. Nursing mothers.

Aponvie Pharmacokinetics


Following administration of a single IV 32 mg dose to healthy subjects, mean (CV%) area under the plasma concentration-time curve (AUC0-∞) was 7.8 (27.4%) mcg·hr/mL and mean plasma concentration at 5 mins postdose was 2.1 (19%) mcg/mL. 


Plasma protein bound: >99%. Mean volume of distribution: ~72 L.


Hepatic (primarily CYP3A4), (minor CYP1A2, CYP2C19). 


Half-life: 12 hours. Mean plasma clearance: 4.4 L/h.

Aponvie Interactions


See Contraindications. Avoid concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) or strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin). May antagonize warfarin (closely monitor INR for 2 weeks after starting each cycle), other CYP2C9 substrates, oral contraceptives (use alternative or backup methods [eg, condoms, spermicides]).

Aponvie Adverse Reactions

Adverse Reactions

Constipation, fatigue, headache.

Aponvie Clinical Trials

See Literature

Aponvie Note

Not Applicable

Aponvie Patient Counseling

See Literature